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Factors Which Determine Compression of Surrounding Structures in Amplatzer
Septal Occluder Following Transcatheter Closure of Atrial Septal Defects
Kazuto Fujimoto, Hiroaki Kise, Hisako Kiguchi, Takanari Fujii, Hideshi Tomita,
Nobuo Oyama, Takashi Soga
Showa University, Northern Yokohama Hospital, Yokohama, Japan
Background: Cardiac erosion and perforation after ASD closure with device have
been reported. Some reports suggest that cardiac erosion may have been associated
with compression of surrounding structures following deployment. However, the risk
factor of the compression of surrounding structures has not yet been clariﬁed. The aim
of this study is to evaluate factors which may determine compression of surrounding
structures following deployment.
Methods: We conducted a retrospective review of all patients with isolated ASD
treated using ASO in our center, until the end of 2013. Various factors in the patient
proﬁle and TEE ﬁndings were compared between the groups with and without change
in compression of surrounding structures following deployment using ANOVA and
logistic regression analysis. Linear regression analysis was performed to assess the
correlation. All p values less than 0.05 were considered signiﬁcant.
Results: Thirty four patients with isolated ASD treated using ASO in our center. The
average age at deployment was 38.1  23.6 with an average long axis defect size of
15.5  5.0mm. There were no multiple and malaligned ASD, but one aneurysmal
ASD. Shorter anterior rim length was associated with compression of aortic wall
(P<0.05). Shorter atrial length and larger ratio of defect size and atrial length were
associated with compression of atrial wall to by the RA disk in the superior side
(P<0.05). All comparisons between the devise size, the existence of ﬂimsy rim, and
compression of surrounding structures following deployment showed no signiﬁcant
difference.
Conclusion: Compression of surrounding structures following deployment may have
been affected not by device size, but by the length of rim, the defect size, and the ratio
between the defect size and the atrial length.O
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TCTAP A-062
Preliminary Clinical Research of PCI Through Transulnar Approach in
Selective Patients with Coronary Artery Disease
Xu Guang Qin, Wei Guo Xiong, Chun Peng Lu, Li Hua Shang
First Afﬁliated Hospital of Tsinghua University, Beijing, China
Background: This study was conducted to assess the safety and feasibility of PCI
through transulnar approach in selective patients with coronary artery diseases.
Methods: 12 patients with stable angina pectoris (male 8,female 4; age 6110.4
years) whose ulnar artery diameter was larger and Allen’s test was positive. We
recorded the puncture time of ulnar artery, CAG time, the success rate of ulnar
puncture and complication rate.
Results: 25 ulnar arteries were punctured successfully, the puncture time was
52.4min, and CAG time was 203.6min.Seventeen lesion segments of ﬁfteen
vessels in 12 patients were implanted stent successfully by 6F guiding catheter.
Conclusion: The ulnar artery might be selected as one access for PCI procedure. It is
safe and effective approach for coronary intervention, and may be widely used in
clinical practice.
TCTAP A-063
Inﬂammatory Effects and Clinical Outcomes of High-pressure Post-dilation with
Non-compliant Balloon During Drug-eluting Stent Implantation
Shao-Ping Nie, Edmundo Patricio Lopes Lao, Xiao Wang, Yin Zhang,
Chang-Sheng Ma
Beijing Anzhen Hospital, Capital Medical University, Beijing, China
Background: The acute inﬂammatory response of high-pressure post-dilation with
non-compliant balloon (HPNC) after drug-eluting stent (DES) deployment remains
still unknown. We sought to evaluate the inﬂammatory effects and clinical outcomes
of HPNC after DES implantation.
Methods: We enrolled consecutive patients with stable angina pectoris, who were
treated with single drug-eluting stent deployed by nominal pressure in de novo
ischemia-related coronary artery. In this per-protocol study, patients were divided into
HPNC group (14atm) or non-HPNC group. The development of inﬂammatory
markers (C-reactive protein and interleukin-6) was used to evaluate the acute in-
ﬂammatory response of HPNC (baseline, 1, 6, 24 and 72 hours after procedure). The
baseline reference vessel diameter, minimal stent diameter soon after DES deploy-
ment, and ﬁnal minimal stent diameter after HPNC were measured by quantitative
coronary analysis. All patients were followed up for 1 year.JACC Vol 63/12/Suppl S j April 22–25, 2014 j TCTAP Abstracts/ORAResults: There was no signiﬁcant difference between the HPNC group (n ¼ 42) and
non-NPNC group (n ¼ 11) with regard to the changes of inﬂammatory markers (CRP,
p ¼ 0.739; IL-6, p ¼ 0.936) within 72 hours after procedure. The minimal stent
diameter after HPNC was larger compared with soon after stent deployment (2.71 
0.43mm vs 2.47  0.41mm, p < 0.001). The percentage to reference vessel diameter
after HPNC was also larger compared with soon after stent deployment (85.5  12.1%
vs 77.9  11.8%, p < 0.001). There was no adverse coronary event in the two groups
at 1 year.
Conclusion: The acute systemic inﬂammatory response induced by HPNC appeared
to be similar to that induced only by stent deployment. HPNC achieved larger stent
diameter, which was associated with similar in-hospital and long-term outcomes
compared with stent deployment only.
TCTAP A-064
Midterm Clinical and Angiographic Outcomes After Placement of Paclitaxel and
Everolimus-eluting Stents for De Novo Native Coronary Stenosis
Tetsuya Ishikawa, Yosuke Nakano, Makoto Mutoh
Saitama Cardiovascular Respiratory Center, Kumagaya, Japan
Background: We conducted a propensity score matched lesion-based comparison of
mid-term clinical and angiographic outcomes after paclitaxel- (PES: TAXUS Liberte)
and everolimus- (EES: XIENCE V / PROMUS and XIENCE Prime) eluting stent
implantation for de novo native coronary stenosis.
Methods: During from February 2009 to August 2012, 1607 nonrandomized
consecutive de novo native coronary lesions treated either with a PES (1028 lesions)
or EES were enrolled in this study, and a retrospective examination was conducted in
August 2013.
Results: The incidences of the clinical endpoint comprising of cardiac death, nonfatal
recurrent myocardial infarction, and deﬁnite stent thrombosis after placement of PES
(1.3%) and EES (0.7%) groups were very low. In the baseline-adjusted angiographic
followed-up lesions (n¼ 471 in each arm), the incidence of binary restenosis (percent
diameter stenosis [%DS] >50%) in the PES group (12.5%) was signiﬁcantly higher
than that in the EES group (3.4%, p<0.001). EES signiﬁcantly related to binary
restenosis TCTAP A-067 (Odds ratio, 0.20; 95% CI, 0.11-0.37; p<0.001).
Conclusion: The present propensity score matched lesion-based analysis ﬁrstly
showed that EES showed the far better mid-term angiographic outcome compared to
PES with statistical equivalent very low incidence of severe cardiac events for de novo
native coronary lesion in Japanese daily practice environment.
TCTAP A-065
To Evaluate Clinical Results of Repeat Drug-eluting Stent (DES) Implantation
for DES Restenosis at Coronary Artery Lesions with High Degree Hinge Motion
Masatsugu Nakano, Toshiya Muramatsu, Reiko Tsukahara, Yoshiaki Itou,
Hiroshi Ishimori, Keisuke Hirano
Saiseikai Yokohama City Eastern Hospital, Yokohama, Japan
Background: There was no report that evaluated clinical results after repeat drug-
eluting stent (DES) implantation for DES restenosis at coronary artery lesions with
high degree hinge motion.
Methods: From April 2007 to December 2009, subjects were serial 133 patients who
underwent repeat154 DES implantation for DES restenosis. Hinge motion by the
difference in the angle between diastole and systole: d angle more than about 20
degree was deﬁned high degree hinge motion in the target lesion. From the base-line
CAG ﬁnding, Patients with DES restenosis at target lesions with high degree hinge
motion were deﬁned as the H group (41 patients,46 stents) and those whose were not
conﬁned high degree hinge motion were deﬁned the Non-H group (92 patients,108
stents). The two groups were compared for 12-month outcomes.
Results: There was no signiﬁcant difference in the percentage of diabetic patients (H:
52.2 vs. Non-H: 56.5%) or target lesions in LAD (H: 50.0 vs. Non-H: 50.9%). The H
group had high rates of stent fracture in stent restenosis site (H: 65.0 vs. Non-H:
15.4%, P¼0.005) than that of Non-H group. At the 12-months clinical results, There
was no signiﬁcant difference in the rate of stent re-restenosis (H: 38.1 vs. Non-H:
27.0%) or second target lesion revascularization (TLR) (H: 23.9 vs. Non-H: 20.4%).
Conclusions: The second TLR rate after repeat DES implantation for DES restenosis
at target lesions with or without high degree hinge motion was similar.
TCTAP A-066
Neo-Atherosclerosis in Drug-eluting Stents Is the Risk of Recurrent Restenosis
Koshi Matsuo, Yasunori Ueda, Ryuta Sugihara
Osaka Police Hospital, Osaka, Japan
Background: Drug-eluting stents (DES) reduced target lesion revascularization
compared with bare metal stent (BMS); however, the restenosis after DES implan-
tation still occurs especially in the late phase. DES restenosis is usually treated by
balloon angioplasty, cutting balloon angioplasty, debulking techniques, and/or DES-
in-DES stenting. Unfortunately, the recurrence of in-stent restenosis (ISR) sometimes
occurs and its mechanisms is unclear. We examined the inﬂuence of in-stent neo-
atherosclerosis as shown by the presence of yellow plaque on ISR recurrence.
Methods: Consecutive 20 patients who received angioplasty for ISR in DES were
prospectively enrolled. Their culprit lesions were examined by angioscopyL/Drug-eluting Stents S19
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19th CardioVascular Summit: TCTAP 2014immediately after intervention for ISR. We evaluated yellow color grade (grade 0-3),
neointima coverage grade (grade 0-2), and thrombus (presence or absence) at the
culprit lesion. The patients were divided into two groups according to the maximum
yellow color grade of the lesion (White: grade 0 or 1 vs. Yellow: grade 2 or 3) and
their ISR recurrence was examined by angiography at one-year follow-up. Diameter
stenosis >50% was deﬁned as ISR.
Results: The incidence of ISR recurrencewas higher in the patientswith yellow ISR lesion
than in those with white ISR lesion (67.8% vs. 10.0%, p¼0.018). Thrombus was not
detected in both groups. Neointima coverage grade was not different between the groups.
Conclusion: The patients with yellow ISR lesion had the higher incidence of ISR
recurrence than those with white ISR lesion.
TCTAP A-067
The Impact of Angiographic Peri-contrast Staining After Second the Impact of
Angiographic Peri-contrast Staining After Second Generation DES
Implantationeneration DES Implantation
Takahiro Tokuda, Toshiya Muramatsu, Reiko Tsukahara, Yoshiaki Ito,
Hiroshi Ishimori, Keisuke Hirano, Masatsugu Nakano, Motoharu Araki, Tamon Kato,
Norihiro Kobayashi, Yasunari Sakamoto, Hideyuki Takimura, Shinsuke Mori,
Hiroya Takafuji, Makino Kenji
Saiseikai Yokohama City Eastern Hospital, Yokohama, Japan
Background: Several studies showed peri-contrast staining (PSS) was be associated
with TLR and very late stent thrombosis. However, the incidence and clinical sequela
of PSS after second generation DES implantation are unclear, so we retrospectively
evaluate the clinical outcomes.
Methods: This study consisted of de novo 1622 lesions in 1150 patients that were
treated with second generation DES (ZES, EES, and BES) in a single center. They
were evaluated by follow-up angiography within 12 months after stent implantation,
from April 2009 to August 2012. We divided into PSS group and non-PSS group and
compared the two groups in clinical and angiographical outcomes.
Results: There were no signiﬁcant differences between the two groups in patient back-
ground and lesion characteristics. Late acquired PSS was observed in 12 lesions (0.74%)
in 11 patients (0.96%). In these lesions, 2 lesions (0.63%) were observed in BES, 4 lesions
(0.4%) were EES and 6 lesions (1.9%) were ZES. (N.S.) Stent fracture was more
frequently observed in lesions with PSS than in lesions without PSS (29.4% versus 1.1%,
P <0.0001). Cumulative incidence of TLR and MACE in the PSS group was higher than
that in the non-PSS group ( 33.3% versus 5.5%, and 41.7% versus 9.6%, P <0.05).
Conclusion: In this study, PSS after second generation DES seemed to be associated
with TLR and MACE.
TCTAP A-068
The Timing of Occurrence of Stent Fracture After Sirolimus-eluting Stent
Implantation
Tomoyuki Fukuzawa, Takahiro Watanabe, Yuichi Hanaki, Seigen I, Hajime Aoki,
Kenichi Kato
Yokohama Rousai Hospital, Yokohama, Japan
Background: SF was more commonly reported in sirolimus-eluting stent (SES), right
coronary artery (RCA), longer duration of implant and longer stent length. However
the timing of stent fracture of each coronary is unknown. The purpose of this study is
to assess the time point at which SF of each coronary occurs by the multidetector
computed tomography (MDCT).
Methods: We performed 64-slice MDCT on asymptomatic and event-free 114 pa-
tients (156 lesions) who received SES implantation. These lesions are all RCA and left
anterior descending artery (LAD) to compare two coronary arteries. We investigated
the rate of SF, in-stent restenosis (ISR) and peri-stent aneurysms caused by SF. MDCT
deﬁnition of SF is complete separation or partial separation of stent struts. The average
ﬁrst CT follow-up period was 24.6months (5-75months). Then we conducted the
second MDCT 42.8 months (12-71 months) later after the ﬁrst MDCT to non-SF 45
patients (48 lesions).
Results: SF was identiﬁed in 32 lesions of 156 lesions (20.5%) at the ﬁrst MDCT. In
RCA, 14 stent fractures of 39 lesions were observed. Fracture rate was 35.8%. In
LAD, 18 stent fractures of 117 lesions were observed. Fracture rate was 15.3%. SF
was more observed in RCA than LAD at the ﬁrst MDCT (P¼0.006). ISR induced by
SF was 1 lesion (3.1%), peri-stent aneurysms were 2 lesions (6.2%). At the second
MDCT, new SF occurred in 3 lesions of non-SF 48 lesions. The rate of new SF was
6.2%. The coronary of new SF was all LAD and new SF didn’t occur at RCA. About
these 3 lesions, ISR and peri-stent aneurysm induced by SF were not detected.
Conclusion: SF was more observed in RCA than LAD at the ﬁrst MDCT, however the
newSFwas identiﬁed in onlyLAD.AboutLAD, it is possibility to increase the rate ofSF in
chronic phase. We continue to follow up the patients who received SES implantation.S20 JACC Vol 63/12/Suppl STCTAP A-069
Clinical and Angiographic Results in Patients with Very Small Coronary Vessel
After Biolimus A9-eluting Stents Implantation
Soichiro Enomoto, Takenori Domei, Shoichi Kuramitsu, Yoshio Kazuno,
Makoto Hyodo, Toru Mazaki, Shinichi Shirai, Kenji Ando
Kokura Memorial Hospital, Kitakyushu, Japan
Background: Percutaneous coronary interventions (PCI) to small-diameter vessels
remain an important challenge because of increased complications.
Methods: Between May 2011 and January 2012, 83 patients with very small coronary
vessels (reference vessel diameter <2.5 mm) were submitted to PCI. Biolimus-eluting
stent (BES) was deployed at a low pressure with long inﬂation time.
Results: Two cases of distal edge dissection were observed and one of them needed
additional stent implantation. Postprocedural TIMI grade 3 ﬂows were achieved in all
patients. There were no death, myocardial infarction (MI) and target lesion revascular-
ization (TLR) during the initial hospitalization. The angiographic data is shown in
Figure. Average luminal diameters(ALD) in distal segments signiﬁcantly increased from
baseline (1.360.49 mm vs. 1.560.31, p<0.01). At 12 months after procedure, the rate
of TLR was 8.0%. There were no cardiac death and MI related to target lesions. Distal
ALD tended to increase from initial procedure (1.710.30mm, p¼0.07).
Conclusion: BES implantation to very small coronary vessels achieved a high clinical
success and luminal diameter distal to stent signiﬁcantly increased and remained
unchanged at 12-month follow-up.TCTAP A-070
One year Clinical, Angiographic, and Optical Coherence Tomography Outcomes
of 2nd Generation Drug Eluting Stents 6 Months Dual Antiplatelet Therapy
Between Biodegradable and Durable Polymer Stent
Byoung Kwon Lee1, Young Won Yoon1, PIl-Ki Min1, Bum-Kee Hong1,
Hyuck Moon Kwon1, Byeong Keuk Kim2, Myeong-Ki Hong2, Yangsoo Jang2
1Gangnam Severance Hospital, Seoul, Korea (Republic of), 2Yonsei University
Cardiovascular Hospital, Seoul, Korea (Republic of)
Background: Stent thrombosis has been strongly associated with discontinuation of
dual antiplatelet therapy. The central point of stent thrombosis seems to be the
impaired, or delayed re-endothelialization, and the most important histological and
morphometric predictors of late stent thrombosis (LST) were endothelial coverage and
the ratio of uncovered to total stent struts after drug-eluting stent (DES) implantation.
However, recent controversies regarding the risk of stent thrombosis in patients receiving
DES has brought up the issue of the appropriate duration of antiplatelet therapy after
percutaneous coronary intervention, and a recent study reported that the use of extended
DAPT for a period longer than 12 months in patients who had received DES was not
signiﬁcantly more effective than aspirin monotherapy in reducing the rate of MI or death
for cardiac causes. While second generation DES promote more favorable vascular
healing comparing to ﬁrst generation DES, biodegradable polymer containing stents
might have a yield in terms of duration of dual antiplatelet therapy (DAPT) than durable
polymer stents. We aimed to test whether biolimus-eluting stent (BES) with 6-month
DAPT would be non-inferior 12-month clinical and angiographic outcome to Zotar-
olimus-eluting stent (ZES) with 6-month DAPT.
Methods: This is a prospective, randomized, open-label, multicenter trial to compare
clinical events and angiographic data between BES and ZES stents. Currently, 621
patients were randomly assigned. The primary end point was a major adverse cardiac
events (MACE) at 12 months. Optical coherence tomography (OCT) at 6 month was
performed in 30 patients of each group. The primary endpoint was MACE, secondary
end points are target lesion failure, in-segment late loss (LL) at 12 months, and
neointimal hyperplasia (NIH) and uncovered stent strut (%) by OCT at 6month.
Results: Currently, clinical follow-up was available in 325 patients and angiographic
follow-up in 311 patients. The primary endpoints were not statistically differentj April 22–25, 2014 j TCTAP Abstracts/ORAL/Drug-eluting Stents
